Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29449840 | 1.00 | NOTUM (0.43) | NOTUMTAAR1GAATLR7CYP1A2 | |
| SCHEMBL8722602 | 0.85 | NOTUM (0.50) | NOTUMCYP1A2CYP2A6LMNATSHR | |
| SCHEMBL27879107 | 0.83 | TAAR1 (0.43) | TAAR1GAACYP1A2CYP2A6LMNA | |
| SCHEMBL1541726 | 0.82 | TRPA1 (0.40) | TAAR1TRPA1TSHRHCAR1ALDH1A1 | |
| SCHEMBL802985 | 0.79 | GAA (0.41) | TAAR1GAACYP1A2CYP2A6LMNA | |
| SCHEMBL22969778 | 0.76 | NOTUM (0.43) | NOTUMCYP1A2CYP2A6LMNATSHR | |
| SCHEMBL1041749 | 0.76 | NOTUM (0.43) | NOTUMCYP1A2CYP2A6LMNATSHR | |
| SCHEMBL17972850 | 0.76 | TAAR1 (0.42) | TAAR1GAALMNABACE1MEN1 | |
| SCHEMBL21718832 | 0.76 | TAAR1 (0.38) | TAAR1GAACYP1A2CYP2A6LMNA | |
| SCHEMBL30728872 | 0.76 | TAAR1 (0.42) | TAAR1GAALMNABACE1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | VIVIDION THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| WO-2024182693-A1 | 2-AZASPIRO[3.3]HEPTANE DERIVATIVES AS STAT3 INHIBITORS FOR THE TREATMENT OF CANCER | VIVIDION THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| CN-118119583-A | Method for producing fluorine-containing aromatic compound | 大金工业株式会社 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023063301-A1 | METHOD FOR PRODUCING FLUORINATED AROMATIC COMPOUND | ダイキン工業株式会社 | 2023-04-20 | — | — | WO | disclosed |
| CN-109153674-B | Iminothiadiazine dioxide derivatives as inhibitors of plasmepsin V of plasmodium | UCB生物制药有限责任公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2022053010-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2022-03-17 | — | — | WO | disclosed |
| US-11136310-B2 | Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors | UCB Biopharma SRL (BE) | 2021-10-05 | — | — | US | disclosed |
| CN-108290860-B | Iminotetrahydropyrimidinone derivatives as PLASMEPSIN V inhibitors | UCB生物制药有限责任公司 | 2021-08-10 | — | — | CN | disclosed |
| EP-3419975-B1 | IMINOTHIADIAZINANE DIOXIDE DERIVATIVES AS PLASMEPSIN V INHIBITORS | UCB Biopharma SRL (BE) | 2021-06-23 | — | — | EP | disclosed |
| EP-3581570-B1 | CARBAZOLE-PYRIDINE-TRIFLUOROMETHYLPHENYL DERIVATIVES AND RELATED COMPOUNDS FOR USE AS TADF LUMINESCENT EMITTERS IN OLEDS | CYNORA GMBH (DE) | 2021-04-21 | — | — | EP | disclosed |
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-17 | — | — | US | disclosed |
| WO-2008003697-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | ABBVIE INC. | 2007-03-01 | — | — | US | disclosed |
| EP-1747206-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-01-31 | — | — | EP | disclosed |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | ABBOTT LABORATORIES | 2006-09-21 | — | — | US | disclosed |
| WO-2006086229-A1 | THE USE OF SELECTIVE P2X7 RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2006-08-17 | — | — | WO | disclosed |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | ABBVIE INC. | 2006-03-09 | — | — | US | disclosed |
| WO-2005111003-A1 | AMINO-TETRAZOLES ANALOGUES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2005-11-24 | — | — | WO | disclosed |
| US-4668830-A | Process for the preparation of compounds containing a difluoromethylene or trifluoromethyl group | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1987-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171733-A1 | Amino-Tetrazoles Analogues and Methods of Use | P2RX7, P2RX2, P2RX5 | NOTUM 4632/4885TAAR1 112/4885GAA 2556/4885 |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | NOTUM 3592/4885TAAR1 511/4885GAA 3200/4885 |
| US-11136310-B2 | Iminotetrahydropyrimidinone derivatives as plasmepsin V inhibitors | PEPD, ADAM17, ANPEP | NOTUM 1609/4885TAAR1 4766/4885GAA 2807/4885 |
| US-20250059161-A1 | COMPOUNDS AND METHODS FOR MODULATING STAT3 | STAT3, JAK2, STAT1 | NOTUM 4817/4885TAAR1 4207/4885GAA 3683/4885 |
| US-20060211739-A1 | Use of selective P2X7 receptor antagonists | P2RX1, P2RX3, P2RX7 | NOTUM 4789/4885TAAR1 130/4885GAA 4313/4885 |
| US-20070049584-A1 | Amino-tetrazoles analogues and methods of use | P2RX7, P2RX2, P2RX5 | NOTUM 4632/4885TAAR1 112/4885GAA 2556/4885 |
| US-20060052374-A1 | Amino-tetrazole analogues and methods of use | P2RX7, P2RX2, P2RX3 | NOTUM 4596/4885TAAR1 126/4885GAA 2529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.